Journal Basic Info
- Impact Factor: 1.809**
- H-Index: 6
- ISSN: 2474-1655
- DOI: 10.25107/2474-1655
Major Scope
- Cancer Clinic
- Vascular Medicine
- Dentistry and Oral Biology
- Anesthesiology and Pain Medicine
- Sleep Medicine and Disorders
- Cardiac Surgery
- Pathology
- Family Medicine and Public Health
Abstract
Citation: Ann Clin Case Rep. 2021;6(1):1948.DOI: 10.25107/2474-1655.1948
Euglycemic Diabetic Ketoacidosis in a Patient with Type 2 Diabetes Mellitus on Sodium- Glucose Cotransporter-2 Inhibitors Induced by COVID-19
AlSaraj F, Krishnareddy K, Capatos G and Medhat P
Department of Endocrinology, Mediclinic Parkview Hospital, Dubai, UAE Intensive Care Unit of Mediclinic Parkview Hospital, Dubai, UAE
PDF Full Text Case Report | Open Access
Abstract:
A 47-years old lady presented to the emergency department complaining of severe symptoms of lower respiratory tract infection of three days duration. She has history of type 2 diabetes on Dapagliflozin, is one of the sodium- glucose cotransporter-2 inhibitor. Clinical, radiological and laboratory tests confirmed the diagnosis of moderate COVID-19 pneumonia and euglycemic diabetes ketoacidosis. The patient admitted to the intensive care unit for better management and discharged home after nine days of hospitalization. We reporting, COVID-19 could induce this serious metabolic abnormality. Therefore, clinicians should be aware of this complication in this current pandemic.
Keywords:
Cite the Article:
AlSaraj F, Krishnareddy K, Capatos G, Medhat P. Euglycemic Diabetic Ketoacidosis in a Patient with Type 2 Diabetes Mellitus on Sodium- Glucose Cotransporter-2 Inhibitors Induced by COVID-19. Ann Clin Case Rep. 2021; 6: 1948..
